Abstract
BackgroundTo investigate the long-term effect of hypertensive phase(HP) on the clinical outcomes of Ahmed Glaucoma Valve (AGV) implantation.MethodThe records of patients with different etiologies of glaucoma who underwent AGV implantation were retrospectively reviewed. HP was defined as the IOP> 21 mm Hg during the first three months after surgery. The main outcome measure was cumulative success defined as 5 < IOP< 21 mmHg and 20 % reduction from the baseline with or without IOP lowering medications. The secondary outcome measures were intraocular pressure (IOP) and the number of glaucoma medications. ResultsA total of 120 patients (28 patients of HP, 92 patients without HP) with an average age (±SD) of 48.9 ± 19.6 years and a mean follow-up of 4.5 ± 1.4 years were enrolled. The mean duration of survival was 5.3 ± 0.5 years in HP which was significantly shorter than 6.4 ± 0.2 years in non-HP. (log Rank= 4.2, P= 0.04) Mean IOP and number of IOP lowering agents were higher in postoperative visits at 1,2, 3, and 4 years in HP patients compared with non-HP. (All Ps < 0.01) Higher Baseline IOP was significantly associated with higher rates of surgical failure. Neovascular glaucoma was the only factor associated with the occurrence of HP in a logistic regression model. (Odds ratio: 3.14 CI: 1.2-8.1). Conclusion In the long-term follow up the duration of survival was significantly longer in the non-HP group. In the non-HP group, the success rate was significantly higher than the HP group
Efficacy and safety of intravitreal bevacizumab in eyes with neovascular glaucoma undergoing ahmed glaucoma valve implantation: 2-year follow-up
